Afrezza Approval Comes With Post-Marketing Trial On Lung Cancer, CV Risk
FDA’s unusually specific request suggests continued worries about safety of MannKind’s inhalable insulin; large trial (8,000-10,000 type 2 diabetics) has a variety of goals.
You may also be interested in...
J&J Innovation's spate of deals led a busy week of deal-making involving many big pharmas. Sanofi exited its inhaled insulin partnership with MannKind, Merck collaborated with Quartet and Complix, Roche partnered with and helped finance C4, and Pfizer signed an immuno-oncology combo trial agreement with Syndax.
During a very brief investor call, MannKind says it is planning to change its pricing and contracting tactics, after being left in the lurch as Sanofi terminates its development and commercialization deal on the inhaled insulin Afrezza.
Novo Nordisk appears not to be worried about any market impact from Afrezza, MannKind’s recently approved inhalable insulin. In an exclusive interview in Copenhagen, the Danish company’s leadership told PharmAsia News that it had taken sufficient steps to maintain its stronghold on the global insulin market.